Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioNTech 4Q Earnings Hit by Drop in Covid Vax Sales | Contract Pharma

What are you searching for?

Sign in
Financial News

BioNTech 4Q Earnings Hit by Drop in Covid Vax Sales

Inventory write-downs by partner Pfizer reduced revenues by €291.3 million in the quarter and €906.7 million for the year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech
4Q Revenues: €1.5 billion (revenues were €4.3 billion 4Q23)
4Q Earnings: €457.9 million (earnings were €2.3 billion 
FY Revenues: €3.8 billion (revenues were €17.3 billion)
FY Earnings: €930.3 million (earnings were €17.3 billion)
Comments: Inventory write-downs by BioNTech’s collaboration partner Pfizer reduced BioNTech’s revenues by €291.3 million and €906.7 million for the three and twelve months ended December 31, 2023, respectively. For the year ended December 31, 2023, R&D expenses were €1.8 billion, compared to €1.5 billion for the comparative prior year period. R&D expenses are mainly influenced by progressing clinical studies for pipeline candidates as well as newly acquired product candidates and the development of variant-adapted COVID-19 vaccines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters